Yours sincerely, Editor
The EMBO Journal REFEREE REPORTS Referee #1 (Remarks to the Author):
This is an interesting manuscript that describes the unexpected interaction of Usp7/Usp11 with the Prc1 complex. It shows that these proteins are involved in ubiquitination of Bmi1 and Ring1 and that they play a role in stability of these proteins on chromatin, resulting in a functional effect on Ink4a expression. All this is very exciting, but some of the experiments are indirect: endogenous pull downs did not all work and the effects on ubiquitination are after overexpression.
There are a number of inconsistencies and questions about the data presented that need to be addressed has only been performed on histone 2a, this is not very useful since the original elderkin paper already shows how unspecific ubiquitination (and presumably deubiquitination) on isolated histone proteins is. The question is whether the nucleosomal H2a is also a target for these DUBs; It would be even more interesting to see if the Usp7 levels affect the H2A ubiquitination levels in the cell, either directly or indirectly through affecting prc1 levels.
A discussion of literature on Usp7 and Usp11 complex formation would be good, e.g. the MDM2/DAXX/Usp7 complex and its relevance to these data, the interactors for Usp7/11 identified in in the large scale MS analysis of the Harper lab (Sowa et al, 2009)do not reflect the PRC1 proteins at all: is there an explanation?
Referee #3 (Remarks to the Author):
This is an interesting study, in which the authors identify the 2 de-ubiquitinating enzymes, USP7 and USP11 associated with proteins of the Polycomb Repressive Complex 1 (PRC1). They show that knockdown of the two proteins leads to decreased levels of BMI1 and MEL18, increased expression of p16INK4a and senescence features. Furthermore, the authors show that BMI1 and MEL18 are expressed at lower levels in USP7 and USP11 knockdown cells, and provide data suggesting that USP7 and USP11 can regulate the ubiquitination levels for BMI1 and MEL18.
The results in the manuscript are novel and interesting to an extensive number of scientists studying transcription, cell cycle control and cancer. I will recommend publication of the manuscript in EMBO J, if the authors address the following comments and questions:
1. The authors state that USP7 and USP11 directly interact with BMI1 and MEL18. This statement appears to based on GST-in vitro binding experiments using GST-purified proteins and in vitro translated lysates. Such an assay does not show that 2 proteins directly interact, since the reticulocyte lysates contain thousands of proteins, which could be required for the interaction. In line with this, the authors show in Fig. 3C that not only BMI1 and MEL18 can interact with USP7, but also CBX8, RING1 and RING2. Although the interactions with all these proteins may be direct, it is not likely.
Since, it would be interesting to know which protein USP7 and USP11 bind to in the PRC1 complex, I propose that the authors perform experiments to address if the interactions between the PSC proteins and USP proteins are direct. Moreover, it would be interesting to know if USP7 and USP11 bind to overlapping regions of BMI1 and MEL18, and whether they can bind at the same time. The presented data suggest that both USP7 and USP11 are required for the stability of BMI1 and MEL18. Does this mean that the function of USP7 is dependent on USP11 and vice versa? 2. The authors show a reduced binding of MEL18 and BMI1 to the INK4a promoter in response to USP7 and USP11 shRNA expression. Is the association of the other members of the PRC1 complex also reduced in response to the down-regulation of USP7 and USP11? What happens to the binding of the PRC2 complex, and how about H2AK119Ub, H3K27me3 and H3K4me3levels? Do the authors find USP7 and USP11 associated with the INK4a promoter?
3. The biological effects of down-regulating USP7 and USP11 could be better characterized. Is the growth rate of the normal fibroblast altered? Are senescence markers increased following inhibition of USP7 and USP11 expression? Is p16INK4a required for the induction of senescence? Does down-regulation of USP7 and USP11 lead to increased p16Ink4a levels and senescence in mouse embryonic fibroblasts? In other words, is the mechanism conserved from human to mouse? 4. BMI1 and MEL18 proteins levels are decreased in response to USP7 and USP11 knockdown. The authors suggest this is due to increased turnover of BMI1 and MEL18. This should be further supported by measuring the half-lives of the proteins with and without USP7 and USP11.
5. Figure 4B : The authors should comment on the lack of correlation between the increased levels of INK4a mRNA and p16INK4a protein.
6. Figure 6B : Why is there no expression of MEL18 in the control treated chromatin fraction? 7. Figure 6C : The authors should also show non-treated control cells and quantify the effect of MG132 on the expression levels of the various proteins.
8. Figure 7A /B: I would expect a change in the total levels for BMI1 and MEL18, when they are less ubiquitinated. Could the authors comment on this? 9. Figure 7B and S7B: The overexpression of the catalytic mutant of USP7 clearly affects the level of MEL18 ubiquitination. This is in contrast to what is stated by the authors. The authors should discuss this finding, which may suggest that USP7 both have a catalytic and non-catalytic effect on MEL18 expression.
10. The authors have not been able to show the association between MEL18, BMI1 and USP7, USP11 at the endogenous levels. The study will obviously be more convincing if this was the case. Referee #1 Figure 2 the input and experiment have been switched accidentally. Some comments on the extra bands would be useful.
Fig1 and 2: the presence of the extra bands moves from the input to the pull-down: most logical explanation is that in
The referee correctly notes that in experiments in which we over-express Flag-tagged proteins, there appear to be extra bands in the immunoprecipitated samples that are not detected in the input sample. This cannot be explained by accidental switching of samples as it is a consistent phenomenon in several independent experiments. The most likely explanation is that the Flag-tagged proteins are subject to a degree of proteolytic cleavage during the immunoprecipitation. While we acknowledge that this is not ideal, the extra bands do not undermine the primary conclusions that the tagged proteins co-precipitate.
Fig 3 and 6: in 3A the S2 fraction shows clear presence of Usp11 and Mel18, but in Fig 6A this has disappeared. What is the explanation?
Although we consistently find USP7 and USP11 associated with chromatin, the proportions recovered in the different subcellular fractions are rather variable between experiments and in different cell types. We suspect that this simply reflects cross-contamination between fractions However, in comparing Fig. 3A and Fig. 6B (presumably what the reviewer intended), USP11 is similarly distributed between S1, S2 and Chr in both experiments. Knockdown of USP11 in Fig. 6 reduces the signal in all three fractions. For MEL18, the situation is complicated by the fact that the protein has multiple post-translationally modified forms that are clearly detectable in the Chr fraction whereas the S1 and S2 fractions show a single band that we suspect is a cross reacting protein.
3. Fig 3c: the amount of CBX8 in the Usp7 pull down is significantly enriched over the input. Is this real? Should that be discussed?
In several different contexts ( Fig. 2A, Fig. 2C , Supplementary Fig S1B) , we have noted that the coprecipitation of CBX8 and USP7 is particularly robust, relative to other PRC1 proteins, and the GST pull down experiment referred to by the reviewer is another manifestation of this phenomenon. However, the signal does not exceed the input because only 2% of the total was used for the input lane. As discussed further in the responses to reviewer #3 (see below), we have used this affinity between USP7 and CBX8 to confirm the co-precipitation of the endogenous proteins (new panel in Fig. 2D ) as well as the direct association of the recombinant proteins (new Fig. 3C ).
Fig7: could the lack of effect of Usp7 catalytic mutant on bmi also be explained by recruitment of usp11? Can you make a double mutant to test this?
We thank the referee for this suggestion and for drawing our attention to published information that USP7 and USP11 interact. We already had evidence for co-precipitation of USP7 and USP11 and have included some of these data (new Fig. 3D ). We also tried co-expressing mutant and wild-type versions of USP7 and USP11 as suggested but in these new experiments the catalytically inactive mutants had no discernible effect on the ubiquitination status of either BMI1 or RING1. We discovered that there was a problem with the plasmid clone used to express His 6 -ubiquitin in some of the experiments reported in the first draft of our paper. We have now extensively repeated the experiments with a new and verified clone of pMT107 and found that the subtle distinctions between USP7 and USP11 that we observed previously were not apparent.
Fig S5
If this experiment has only been performed on histone 2a, this is not very useful since the original elderkin paper already shows how unspecific ubiquitination (and presumably deubiquitination) on isolated histone proteins is. The question is whether the nucleosomal H2a is also a target for these DUBs; It would be even more interesting to see if the Usp7 levels affect the H2A ubiquitination levels in the cell, either directly or indirectly through affecting prc1 levels.
We agree that a more stringent assessment of whether USP7 or USP11 can de-ubiquitinate H2A or H2B would be to conduct the experiment with purified nucleosomes. We had indeed performed such an experiment using nucleosomes containing Flag-tagged H2A and confirmed that USP7 can deubiquitinate uH2A under these conditions whereas USP11 can not. These data are now included in the revised manuscript ( Supplementary Fig. S6C ). However, we were unable to confirm whether USP7 can also de-ubiquitinate H2B because mammalian cells contain relatively low levels of uH2B (compared to Drosophila or yeast). As discussed in the text, we did not observe increased levels of uH2A or uH2B following knock-down of USP7 or USP11. As an alternative approach, we asked whether over-expression of these USPs or their catalytically inactive derivatives, would reduce the total pools of uH2a and uH2B. As illustrated in Supplementary Fig. S6D , there was no discernible change in the levels of these modified histones following ectopic expression of either USP7 or USP11. However, these assays were conducted in the presence of excess His-ubiquitin and in our experience this can cause general stabilisation of ubiquitinated proteins. Similarly, we noted that catalytically inactive USP7 and USP11 caused a significant increase in both uH2A and uH2B, presumably due to indirect effects.
6.
A discussion of literature on Usp7 and Usp11 complex formation would be good, e.g. the MDM2/DAXX/Usp7 complex and its relevance to these data, the interactors for Usp7/11 identified in in the large scale MS analysis of the Harper lab (Sowa et al, 2009 ) do not reflect the PRC1 proteins at all: is there an explanation? We thank the referee for this suggestion and have included new data confirming the interaction between USP7 and USP11, as noted by Sowa et al (2009) . We have also referred extensively to these interaction studies but do not see why the MDM2/DAXX/USP7 complex is particularly relevant to our conclusions, other than as a potential mediator of the growth arrest following knockdown of USP7 (already mentioned in the text). While it is perhaps surprising that PRC1 proteins did not appear in the lists of USP interactors reported by Sowa et al., such large scale proteomic approaches tend to focus on the more abundant interacting proteins and at this juncture, we do not know what proportion of the USP7 or USP11 in the cell is associated with PRC1 complexes. It is also curious that USP7 and USP11 appear to have quite different clients in these screens despite interacting with one another. We would also point out that we are not alone in finding USP7 associated with PRC1 complexes, as indicated in the Discussion.
Referee #3
1. The authors state that USP7 and USP11 directly interact with BMI1 and MEL18. This statement appears to based on GST-in vitro binding experiments using GST-purified proteins and in vitro translated lysates. Such an assay does not show that 2 proteins directly interact, since the reticulocyte lysates contain thousands of proteins, which could be required for the interaction. In line with this, the authors show in Fig. 3C that not only BMI1 and MEL18 can interact with USP7, but also CBX8, RING1 and RING2. Although the interactions with all these proteins may be direct, it is not likely. Since, it would be interesting to know which protein USP7 and USP11 bind to in the PRC1 complex, I propose that the authors perform experiments to address if the interactions between the PSC proteins and USP proteins are direct. Moreover, it would be interesting to know if USP7 and USP11 bind to overlapping regions of BMI1 and MEL18, and whether they can bind at the same time.
Although the referee is correct in pointing out that reticulocyte lysates contain many cellular proteins that could in principle facilitate the interactions we observe, they are generally present at much lower concentrations than the proteins under study. However, to assuage these concerns, we have repeated the pull-down assays using recombinant proteins produced in either E. coli or in insect cells (new Fig. 3C ). As these proteins were extensively purified and appear as single bands on SDS-PAGE, the data confirm that USP7 and USP11 interact directly with MEL18, BMI1, CBX8 and RING1.
As they also imply that the original GST-pull down assays, using in vitro translated target proteins, were providing reliable information, we have used this simpler approach to address whether USP7 and USP11 bind to the same or overlapping domains. Using a set of MEL18 deletion mutants, we find that USP7 and USP11 bind to the amino terminal region of the protein that includes the eponymous RING domain. While it would of course be interesting to extend these analyses to other PRC1 components, the number of potential interactions make this a daunting prospect that we think is beyond the remit of this study.
The presented data suggest that both USP7 and USP11 are required for the stability of BMI1 and MEL18. Does this mean that the function of USP7 is dependent on USP11 and vice versa? This is very interesting question and as discussed above in the response to referee #1, we have included data showing that USP7 and USP11 interact with one another suggesting that they might be present within the same complex. Although we have not formally proved this point (which would require sequential immunoprecipitation of the endogenous proteins), we note that knockdown of USP7 results in a reduction of USP11 protein but not RNA levels ( Supplementary Fig. S7C ).
The authors show a reduced binding of MEL18 and BMI1 to the INK4a promoter in response to
USP7 and USP11 shRNA expression. Is the association of the other members of the PRC1 complex also reduced in response to the down-regulation of USP7 and USP11? What happens to the binding of the PRC2 complex, and how about H2AK119Ub, H3K27me3 and H3K4me3levels? Do the authors find USP7 and USP11 associated with the INK4a promoter?
We have previously shown that multiple PRC1 complexes can bind simultaneously to the INK4a locus and that shRNA-mediated ablation of BMI1, for example, causes displacement of MEL18 and a reduction of H3K27me3 at the locus (Maertens et al 2009 PLoSOne). The prediction, therefore, is that USP7 and USP11 shRNAs will affect the binding of other PRC1 components. We have conducted additional experiments to confirm this ( Supplementary Fig. S4 ) but apart from taking time, we do not see what purpose would be served by extending the analyses to all of the modifications mentioned by the reviewer.
We have naturally tried to determine whether USP7 and USP11 also associate with the INK4a promoter region. Although we have been able to ChIP the INK4a region with USP7 and USP11 antibodies, we are not yet confident about the specificity of the binding and prefer not to include the data at this point.
3. The biological effects of down-regulating USP7 and USP11 could be better characterized. Is the growth rate of the normal fibroblast altered? Are senescence markers increased following inhibition of USP7 and USP11 expression? Is p16INK4a required for the induction of senescence? Does down-regulation of USP7 and USP11 lead to increased p16Ink4a levels and senescence in mouse embryonic fibroblasts? In other words, is the mechanism conserved from human to mouse?
We are happy to provide additional indicators that the cells transduced with USP7 and USP11 shRNAs adopt characteristics of senescence. For example, their proliferation is demonstrably inhibited, they stain positively for SA-beta gal activity and have single prominent nucleoli (new panels in Fig. 4 ). We also determined whether shRNA-mediated knock-down of USP7 or USP11 would have the same effect in the Leiden strain of human fibroblasts which are homozygous for an inactivating mutation in p16 INK4a . In our opinion, this is the most direct and reliable approach to assess whether the arrest is p16-dependent. As shown in the new Fig. 5 , the arrest caused by USP11 shRNA is p16-dependent whereas the arrest caused by USP7 shRNA is not. The implications are discussed in the revised text.
The referee also asks whether the "mechanism" is conserved in mouse cells. To our knowledge, there are no reasons to suspect that mouse and human Polycomb group proteins operate by different mechanisms. Otherwise, there should be a strict requirement that observations made using mouse knockouts are validated in human cells. Presumably the question relates to the documented differences in the regulation of the mouse and human Ink4a/Arf loci and the fact that mouse Arf plays a more prominent role in senescence. An expectation would be that USP7 or USP11 knockdown will cause MEFs to arrest via an Arf-dependent mechanism but the situation could be complicated by the role of USP7 in the p53/MDM2 network. As these issues are not germane to our conclusions, we do not think it is warranted to re-do the experiments in MEFs, requiring the generation and validation of a new set of mouse-specific reagents.
4. BMI1 and MEL18 proteins levels are decreased in response to USP7 and USP11 knockdown. The authors suggest this is due to increased turnover of BMI1 and MEL18. This should be further supported by measuring the half-lives of the proteins with and without USP7 and USP11. We had already tried to do the suggested experiment but found that adding cycloheximide to the cells causes an increase in the phosphorylation of BMI1 and MEL18. Splitting of the signal into multiple bands makes it difficult to calculate half lives by immunoblotting and our attempts to resolve the multiple species into a single band, for example by using calf-intestinal or lambda phosphatase, were unsuccessful. Figure 4B : The authors should comment on the lack of correlation between the increased levels of INK4a mRNA and p16INK4a protein.
5.
We are also uncomfortable about the sporadic lack of correlation between knock-down and effect but note that it appears to be a general problem, not only in our own work but also in reports from other labs. The only solution we have in the short term is to reproduce the qualitative effects in multiple experiments and with multiple shRNAs.
Figure 6B: Why is there no expression of MEL18 in the control treated chromatin fraction?
The signal for MEL18 in Fig 6B is lower than in Fig. 6A -this is due to batch to batch differences in commercially available antibodies.
7. Figure 6C : The authors should also show non-treated control cells and quantify the effect of MG132 on the expression levels of the various proteins. In our opinion, this request is unjustified. As the MG132 is dissolved in DMSO, it is entirely appropriate to use 0.1% DMSO as the control. There is no reason to suspect that this concentration of DMSO will affect the stability or expression of the proteins under investigation. Similarly, what useful information would be gained from quantifying the effects? The purpose of the figure is simply to demonstrate that the levels of BMI1 and MEL18 are enhanced by inhibiting the proteasome.
8. Figure 7A /B: I would expect a change in the total levels for BMI1 and MEL18, when they are less ubiquitinated. Could the authors comment on this? In our experience, transfecting cells with His6-ubiquitin (as in the experiments described in Fig. 7) can dramatically increase the levels of proteins that are targeted by the proteasome (supporting data available if required), presumably because the degradative machinery becomes saturated. This is likely to mask the any effects on protein stability following modulation of USP7 or USP11 expression. However, in other contexts, we generally see enhanced levels of BMI1 when it is coexpressed with the USPs. 9. Figure 7B and S7B: The overexpression of the catalytic mutant of USP7 clearly affects the level of MEL18 ubiquitination. This is in contrast to what is stated by the authors. The authors should discuss this finding, which may suggest that USP7 both have a catalytic and non-catalytic effect on MEL18 expression. The referee correctly notes that the catalytic mutant of USP7 appears to reduce the ubiquitination of BMI1 and MEL18, but may have misunderstood our statements to this effect on page 13 and in the discussion on page 15. However, this point is no longer an issue as in the revised manuscript we include new data showing that when His-Ub expression is optimised, the catalytic mutants of USP7 and USP11 are unable to block the ubiquitination of BMI1, MEL18 and RING1.
10. The authors have not been able to show the association between MEL18, BMI1 and USP7, USP11 at the endogenous levels. The study will obviously be more convincing if this was the case. We agree and, given the strength of the in vitro binding to CBX8, have revisited the issue using an affinity purified antibody against CBX8. As shown in Fig. 2D , we can confirm the co-precipitation of endogenous USP7 and USP11 with endogenous CBX8
Editorial Decision 19 May 2010
The paper has been re-reviewed by one original referee with no further comments.
